Compare Adaptive Biotechnologies Corp (ADPT) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.5 (market cap $20.14M). The key difference: Adaptive Biotechnologies Corp is far larger — about 165.3× Avalanche Treasury Corporation Class A Common Stock's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ADPT | AVAT | |
|---|---|---|
Market Cap | $3.33B | $20.14M |
Sector | Health | Financials |
52-Week High | $22.37 | $10.75 |
52-Week Low | $10.24 | $0.51 |
Enterprise Value | $3.19B | $20.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AVAT trades at $0.5114, down 3.22% today, with a bearish technical signal from moving averages and a neutral oscillator reading. The company reported a net income of $8.28 million for 2025 but shows negative operating cash flow of -$930,710. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is cautious due to weak cash flow and bearish technicals, though low P/E and P/B ratios may appeal to value investors. Key risks include operational sustainability and market sentiment shifts. Analyst consensus is not yet established post-listing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
